The Oncology Institute
Welcome,         Profile    Billing    Logout  
 0 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chand, Arati
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
NCT05002777 / 2021-001671-16: Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Hourglass Jul 2024 - Dec 2024 : Data from trial for warm autoimmune hemolytic anemia
Active, not recruiting
2
22
Europe, US, RoW
rilzabrutinib, PRN1008/SAR444671
Sanofi, Sanofi Aventis Recherche et Developpement
Warm Autoimmune Hemolytic Anemia (wAIHA)
05/24
05/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT05593094: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
210
Europe, US, RoW
ZN-A-1041 50mg BID, ZN-A-1041 Enteric Capsules, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID, ZN-A-1041 400mg BID, ZN-A-1041 600mg BID, ZN-A-1041 800mg BID, ZN-A-1041 1000mg BID, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
Suzhou Zanrong Pharma Limited
Advanced Solid Tumors, HER2-positive Breast Cancer
10/25
10/26
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
Posadas, Leslie
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
NCT05593094: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
210
Europe, US, RoW
ZN-A-1041 50mg BID, ZN-A-1041 Enteric Capsules, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID, ZN-A-1041 400mg BID, ZN-A-1041 600mg BID, ZN-A-1041 800mg BID, ZN-A-1041 1000mg BID, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
Suzhou Zanrong Pharma Limited
Advanced Solid Tumors, HER2-positive Breast Cancer
10/25
10/26
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT05485974: A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Recruiting
1
44
US
HBI-2438
HUYABIO International, LLC.
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
08/25
08/25

Download Options